Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enalapril + hydrochlorothiazide is a fixed-dose combination oral medication used to treat high blood pressure (hypertension). It contains two active ingredients with complementary mechanisms of action. Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure by blocking the formation of angiotensin II, a substance that causes blood vessels to constrict; this results in vasodilation and reduced workload on the heart. Hydrochlorothiazide is a thiazide diuretic ("water pill") that reduces blood pressure by increasing renal excretion of sodium and water, thereby decreasing plasma volume. The combination provides additive antihypertensive effects and may be used when monotherapy with either agent alone does not adequately control blood pressure[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on enalapril + hydrochlorothiazide.